ERBB2 and breast cancer: However, in August 2022, Fam‐trastuzumab deruxtecan was approved by the FDA for patients with unresectable or metastatic HER2‐low breast cancer who have received prior chemotherapy in the metastatic setting or developed disease recurrence.